{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001886","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.778392+00:00","generated_at":"2026-06-20T18:33:59.011470+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Northwest Biotherapeutics shareholders approve all six proposals at 2022 annual meeting","bullets":["Re-elected directors Linda F. Powers and Navid Malik with 97.2% and 97.5% of votes cast respectively.","Ratified Cherry Bekaert LLP as auditor for FY2022 with 98.8% of votes cast.","Approved increase of authorized common shares from 1.2B to 1.7B with 95% of votes cast (73.8% of outstanding common).","Approved advisory say-on-pay for 2021 executive compensation with 91.9% support.","Ratified 2020 option awards to executives and independent directors with over 90% approval each."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001886","json":"https://secwatch.observer/filing/0001104659-23-001886.json","markdown":"https://secwatch.observer/filing/0001104659-23-001886.md","text":"https://secwatch.observer/filing/0001104659-23-001886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/tm231540d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:33:59.011470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bdf8225ec58dc7f894e2a8c15823f3df5bf628f","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of previously reported 2020 option awards to the Company's independent directors at the 2022-12-30 meeting.","evidence_excerpt":"The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2020 Option Awards to the Company's Independent Directors 619,934,754 (90.4%) 65,686,803 (9.6%) 8,392,803 (N/A) 147,209,551 (N/A)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"},{"claim_id":"1f39dc50659b5d6668a68de4ed3e4e55bdc24e75","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Election of Directors at the 2022-12-30 meeting.","evidence_excerpt":"The votes for Ms. Powers and Dr. Malik were as follows: For Withheld Broker Non-Votes Ms. Linda F. Powers 674,562,624 (97.2%) 19,451,736 (2.8%) 147,209,551 (N/A) Dr. Navid Malik 676,764,972 (97.5%) 17,249,388 (2.5%) 147,209,551 (N/A)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"},{"claim_id":"62c7667972bc0ffa98186f6caed83fc5c21074c5","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 1,200,000,000 to 1,700,000,000 at the 2022-12-30 meeting.","evidence_excerpt":"The votes for approval by the common and preferred stockholders, voting together as a single class, as a percentage of votes cast, and as a percentage of the total outstanding shares of Common and Preferred Stock combined as of the record date, were as follows: For Against Abstained Broker Non-Votes Common Stock Increase Amendment 799,877,480 37,214,287 4,132,144 0 Percent of votes cast (95.1%) (4.4%) (0.5%) Percent of total Common & Preferred Stock (74.3%) (3.5%) (0.4%)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"},{"claim_id":"c1e3092726f1feac8c4b81274b392d809032dbfa","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of Appointment of Cherry Bekaert LLP as the independent registered public accounting firm at the 2022-12-30 meeting.","evidence_excerpt":"The votes for appointment of Cherry Bekaert were as follows: For Against Abstained Broker Non-Votes Ratification of Cherry Bekaert LLP 829,094,918 (98.8%) 9,951,520 (1.2%) 2,177,473 (N/A) 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"},{"claim_id":"d6c7855bb20c9448da04dae5c9b57b6bfbdc02c3","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of the same option awards made in 2020 to the Company's named executive officers at the 2022-12-30 meeting.","evidence_excerpt":"The votes for ratification were as follows: For Against Abstained Broker Non-Votes Ratification of Named Executive Officer Option Awards 613,009,482 (90.0%) 68,146,624 (10.0%) 12,858,254 (N/A) 147,209,551 (N/A)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"},{"claim_id":"d704d4f93e0f54b29a89e47d69658c3528e0361b","claim":"NORTHWEST BIOTHERAPEUTICS INC shareholders approved Advisory vote on 2021 executive compensation at the 2022-12-30 meeting.","evidence_excerpt":"The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2021 Executive Compensation 625,747,069 (91.9%) 55,153,546 (8.1%) 13,113,745 (N/A) 147,209,551 (N/A)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923001886/0001104659-23-001886-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}